CDT Equity Inc (CDT) Fair Value & Analysis
Healthcare · US · Market cap $5.0M
CDT Equity Inc
CDT · US
Fair value as of: Jul 15, 2026
From 1 valuation models · updated today
Fair value updated Jul 15, 2026 — revised from $1,171 to $0.3782 (−100.0%) since Jun 24, 2026. Share price −49.7% over the past month.
Price vs Fair Value (12 months)
12‑month range $0.3500 – $482.00 · fair‑value band $0.2823 – $0.5645 · the $0.3500 price screens below the $0.3782 fair value. As of Jul 15, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
CDT Equity Inc (CDT) currently trades at $0.3500, while our model-based Fair Value estimate is $0.3782 — implying the stock looks roughly 8.1% fairly valued today. We read business quality at 24/100 (below-average quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: low) — always confirm before acting.
Net debt stands at $896M. Fundamentals as of Jul 15, 2026
Our scenario range runs from $0.2823 (bear case) to $0.5645 (bull case); at $0.3500, the current price sits within that range. For context, the median of 10 Healthcare peers we cover trades at -32% fair-value upside — at 8%, CDT screens cheaper than that median.
Key figures & financial health
Figures from reported company fundamentals (EODHD) · as of Jul 15, 2026. TTM = trailing twelve months.
About the company
CDT Equity Inc., a data-driven biopharmaceutical company, focuses on identifying, enhancing, and monetising therapeutic assets. The company's pipeline includes AZD1656, a glucokinase activator that is in Phase II trials for the treatment of autoimmune disorders, including uveitis, Hashimoto's thyroiditis, preterm labor, and renal transplant; AZD5658, which is in Phase I clinical trial for the treatment of Type 2 Diabetes Mellitus; and AZD5904, which has completed Phase I clinical trials for the treatment of idiopathic male infertility. It also provides treatments for inflammatory disorders, oncology, dermatology, rare diseases and animal health. The company was formerly known as Conduit Pharmaceuticals Inc. and changed its name to CDT Equity Inc. in August 2025. The company was founded in 2019 and is based in Naples, Florida.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
CDT Equity Inc reported revenue of $2.7B in FY2025 versus $0 in FY2021. Reported net income was −$39.2M in FY2025.
Is CDT fairly valued? → Check now
Similar stocks
10 more Biotechnology stocks, each showing price versus our Fair Value estimate (as of Jul 15, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Vertex Pharmaceuticals Incorporated VRTX34 | R$562.61 | R$385.38 | -32% |
| Regeneron Pharmaceuticals, Inc REGN34 | R$52.30 | R$9.67 | -82% |
| UCB SA UCB | €274.90 | €211.40 | -23% |
| argenx SE ARGNF | $900.00 | $382.64 | -57% |
| Samsung Biologics Co 207940 | 1,000,000 KRW | 1,011,109 KRW | +1% |
| CSL Limited CSL | A$97.91 | A$100.60 | +3% |
| Celltrion, Inc 068270 | 171,400 KRW | 74,280 KRW | -57% |
| BioNTech SE B1NT34 | R$27.80 | R$23.67 | -15% |
| Moderna, Inc M1RN34 | R$12.44 | R$5.11 | -59% |
| Innovent Biologics, Inc 1801 | HK$85.35 | HK$21.13 | -75% |
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is CDT Equity Inc (CDT) undervalued?
What is the fair value of CDT?
What is the quality score of CDT?
What is the net profit margin of CDT?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Unlock the full CDT Equity Inc analysis — and try Pro free
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.
Not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.